Ribavirin: recent insights into antiviral mechanisms of action
- PMID: 12825459
Ribavirin: recent insights into antiviral mechanisms of action
Abstract
Ribavirin, a nucleoside analog, used in combination with interferon-alpha (IFN alpha) results in a substantial improvement in the sustained virologic response in chronic hepatitis C. Identified antiviral mechanisms of action for ribavirin include: (i) inhibition of viral encoded polymerases; (ii) inhibition of genomic RNA capping; and (iii) inhibition of cellular encoded enzymes that control de novo synthesis of purine nucleosides. More recently, ribavirin has been shown to engender a bias toward helper T-cell (CD4+) type 1 (Th1) cytokine responses in models of immunity. Recent detailed analysis has also shown that ribavirin can be utilized and incorporated by the polio viral polymerase into genomic and antigenomic transcripts, and is capable of base pairing with either UMP (uridine monophosphate) or CMP (cytidine monophosphate). This results in ribavirin-mediated mutagenesis of the viral genome and has the potential to push the virus beyond tolerable set points in its mutation rate, leading to an overall reduced fitness of the viral population. Of the many mechanisms of action demonstrated for ribavirin, the current clinical trials of selective inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors and immunomodulating agents in hepatitis may facilitate our understanding of what activity (if any) predominates when ribavirin is used in combination with IFN alpha.
Similar articles
-
Metabolism and antiviral activity of ribavirin.Virus Res. 2005 Feb;107(2):165-71. doi: 10.1016/j.virusres.2004.11.006. Virus Res. 2005. PMID: 15649562 Review.
-
Treating HCV with ribavirin analogues and ribavirin-like molecules.J Antimicrob Chemother. 2006 Jan;57(1):8-13. doi: 10.1093/jac/dki405. Epub 2005 Nov 17. J Antimicrob Chemother. 2006. PMID: 16293677 Review.
-
In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.Antimicrob Agents Chemother. 2004 Nov;48(11):4387-94. doi: 10.1128/AAC.48.11.4387-4394.2004. Antimicrob Agents Chemother. 2004. PMID: 15504868 Free PMC article.
-
Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications.Virus Res. 2005 Feb;107(2):173-81. doi: 10.1016/j.virusres.2004.11.007. Virus Res. 2005. PMID: 15649563 Review.
-
Mechanisms of action of ribavirin against distinct viruses.Rev Med Virol. 2006 Jan-Feb;16(1):37-48. doi: 10.1002/rmv.483. Rev Med Virol. 2006. PMID: 16287208 Free PMC article. Review.
Cited by
-
Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.Gut. 2020 Jan;69(1):158-167. doi: 10.1136/gutjnl-2018-317065. Epub 2019 Mar 4. Gut. 2020. PMID: 30833451 Free PMC article.
-
The induction of type I interferon production in hepatitis C-infected patients.J Interferon Cytokine Res. 2009 May;29(5):299-306. doi: 10.1089/jir.2008.0092. J Interferon Cytokine Res. 2009. PMID: 19232000 Free PMC article.
-
Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance.World J Hepatol. 2015 Nov 8;7(25):2590-6. doi: 10.4254/wjh.v7.i25.2590. World J Hepatol. 2015. PMID: 26557951 Free PMC article. Review.
-
The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.Med Res Rev. 2011 Jan;31(1):42-92. doi: 10.1002/med.20176. Med Res Rev. 2011. PMID: 19714577 Free PMC article. Review.
-
M Segment-Based Minigenome System of Severe Fever with Thrombocytopenia Syndrome Virus as a Tool for Antiviral Drug Screening.Viruses. 2021 Jun 3;13(6):1061. doi: 10.3390/v13061061. Viruses. 2021. PMID: 34205062 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials